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A MOUSE polyclonal antiserum against Trypanosoma cruzi
or its IgG and IgM fractions and five monoclonal anti-
bodies (two IgM, two IgG1 and one IgG2a) recognize and
combine with membrane components of trypomastigote
forms of the parasite as revealed by immunofluorescence.
Although all these antibodies sensitize trypomastigotes
and prepare them to activate the complement (C) system,
as measured by consumption of total C, C4, B and C3, only
the polyclonal antiserum or its IgG, IgM and Fab/ frag-
ments were able to induce trypanosome lysis by the
alternative C pathway.
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Introduction
Trypomastigote forms of Trypanosoma cruzi (TF),
a non-replicative and non-activator of alternative
complement pathway (ACP), can be experimentally
transformed into activators ofACP upon treatment
with proteolytic enzymes, heating at 45C2 or
incubation with some types of specific immuno-
globulins.
3 These observations indicate that the
forms of trypomastigotes, during their differentia-
tion either from epimastigotes (EF) (the replicative,
non-infective activators ofACP found in the gut of
the insect vector) or from amastigotes present
essentially inside the cells of the vertebrate hosts,
synthesize and express on their cell surface
regulatory proteins ofC activation (RPC) which are
biologically similar to those found on vertebrate
cells or plasma.4’5 Activation of the C system
depends on the formation of the C3 convertases,
C4b2a and C3bBb.6 These two bimolecular enzyme
complexes activate C3 and some of the C3b formed
in turn attaches to the target. In plasma factor H,
7
C4-binding protein (C4bp)
8 and on tissue, C
receptor type one (CR1),
9 decay-accelerating factor
(DAF)
l and membrane cofactor protein (MCP)s
restrict the activity of C4b and C3b and thereby
inhibit C activation. Among these RPC a DAF-like
glycoprotein, cognominated T-DAF, has been
described on the T. cruzi cell surface2’11’12 and
recently has been partially cloned.
13
Patients with Chagas’ disease, or mice exper-
imentally infected with T. cruzi produce antibodies
that can be detected by the conventional immuno-
logical methods,
14 some of them, but not all, being
able to prepare, in vitro, the TF for C-mediating lysis
through ACP.
15 The fragments F(ab’)2, Fab’ and
Fab prepared from these immunoglobulins retain
that activity even when the ability to serve as
acceptors for C3b is restrained by additional
reduction and alkylation of the Fd interchain
disulphide bonds.
15 Therefore, the C-mediated lysis
of TF by immunoglobulins (Igs), thought to be
induced through the ACP, is restricted to some
antibody populations and depends on the presence
of an intact Fc portion and accessible acceptors for
C3b on their Fab moieties. Thus, the transformation
of TF into ACP activating particles by those Igs
could be related to the epitopes recognized rather
than to the Igs isotype. In this report selected
monoclonal and polyclonal antibodies anti-T, cruzi
were used to sensitize TF and the ability of
sensitized trypomastigotes to activate C and to
become susceptible to C attack are illustrated. These
results reinforce the idea that the Igs inducing
trypomastigote C-mediating lysis block some
RPC-.like molecules present on the parasite cell
surface.
(C) 1992 Rapid Communications of Oxford Ltd
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Materials and Methods
Sera, mAbs, IgM, IgG and Fab#: Immune mouse
sera (IMS) were obtained from mice 12 weeks
after an infection with 1 x 103 of TF and
contained Abs anti-T, cruzi as assayed by ELISA
(1 1200), indirect immunofluorescence (IIF) (1 50),
C fixation reaction (+ + +) and by the ability to
sensitize TF for C-mediating lysis. Normal human
serum (NHS), normal mouse serum (NMS), and
normal guinea pig serum (NGpS) were obtained
from individuals or animals devoid of specific Abs
for T. cruzi assayed as above. Monoclonal
antibodies A1 (lgM mAb H3G6), A2 (IgM mAb
L1D10), A3 (IgG mAb L2B11), A4 (IgG2a mAb
6A2), A5 (IgG1 mAb B10.1)
a6 and the polyclonal
IgG (A6) and IgM (A8) and its Fab/i (A9) from
IMS (A7), were prepared in our laboratories. Goat
anti-mouse IgG or IgM conjugated with FITC
(Sigma Chemical Corp., USA) and rabbit serum (A)
anti-sheep red blood cells (Es) were also prepared
in our laboratories.
Parasite: TF (Y strain), free of antibodies against
T. cruzi were obtained from blood of mice
pretreated with cyclophosphamide (200mg/kg).
Five days after an infection with 1.5 x 10 T. cruzi
the animals were bled and the parasites suspended in
Minimum Essential Medium (MEM) and the
concentration adjusted to 2.6 x 106 parasites/ml2.
Sensitization of trypanosomes withA bs, activation ofC system
and C-mediating sis: One hundred microlitre samples
of TF were mixed with equal volumes of NMS,
mAbs, IMS or with their IgG, IgM or Fab/t
fragments and incubated for 30min at 4C. 15
After washing, the presence of specific Igs on the
parasite cell surface was examined by IIF technique
using anti-Igs-FITC as probe. A volume of NHS
as C source was added and the mixture was
reincubated for 1 h at 37C and the number of
motile parasites determined using a haemocyto-
meter. The parasites were removed by centrifuga-
tion and the supernatants were saved for C
titrations. Total C was measured by determining the
number of CH50 remaining in the samples of NHS
incubated with pre-opsonized TF using sheep red
blood cells (Es) pre-sensitized with rabbit serum
anti-E (EA) in pH 7.4 isotonic veronal buffered
saline containing 0.1% gelatin, 15 mM CaC12 and
5 mM MgC12 (VBS + +). The components C4 and
C3 were measured by determining the number of
haemolytic active molecules (Z) remaining in the
samples of NHS incubated with pre-opsonized TF
using EAC1 or EsAC142 intermediate cells,
respectively, in VBS + + containing 2.5% of glucose
(DGVBS + +).aT Factor B was measured by
determining the number of haemolytically active
molecules (Z) remaining in the sample of NHS
incubated with pre-opsonized TF using rabbit red
blood cells (Er) and NHS previously depleted of
factor B in DGVBS++ containing 1 mM Mg2+
and 10 mM EGTA.
18
Results
Presensitization of trypomastigotes with different antibodies
against T. cruzi: The monoclonal antibodies A1 (IgM
mAb H3G6), A2 (IgM mAb L1D10), A3 (IgG,
mAb L2Bll), A4 (IgGz mAb 6A2), A5 (IgGa mAb
B10.1) and the polyclonal antibodies A6 (anti-
T. cruzi IgG), A7 (anti-T. cruzi chronic mouse
serum), A8 (anti-T. cruzi IgM) and A9 (anti-T. cruzi
Fab#) are able to recognize and combine with
epitopes present on the TF cell surface membrane
as revealed by IIF. The opsonized trypanosomes
presented uniform, linear deposits of mouse IgG or
IgM on their surfaces (data not shown).
Activation of C system by trypomastigotes bearing antibodies
on their cell surface: TF pre-opsonized with the anti-
T. cruzi antibodies present in the samples when
incubated with NHS under conditions allowing
activation of either the classical and the alternative
C pathway induce an extensive reduction in the
number of CHs0 (Fig. 1A), and in the number of
haemolytically active molecules of C4 (Fig. 1B),
factor B (Fig. 1C) and C3 (Fig. 1D).
Ability of specific Abs of mediating T. cruzi C ysis:
Trypanosome lysis, as evaluated by comparing the
number of motile parasites at the beginning and at
the end of the incubation period of pre-opsonized
TF with NHS, as C source, was only seen when
parasites were presensitized with the polyclonal
specific antiserum, or with their Igs, IgG or IgM,
and to a lesser extent, with their Fab/t (Table 1).
Discussion
The T. cruzi infection in humans induces the
production of Abs directed to several parasite
epitopes and belonging to different Ig isotypes.
19
The appearance of these Abs coincides with the first
signals of the infection, remaining high during the
acute phase of the disease,g The Abs capable of
sensitizing trypomastigotes for C mediated lysis
follow a similar pattern but it has been shown that
they become undetectable in some patients treated
with therapeutic drugs.
14 These antibodies or their
F(ab’)2 or Fab fragments as noted earlier, are known
to transform trypomastigotes into ACP activators,
15
a suggestion that was reinforced by two recent
observations: first, the demonstration that trypo-
mastigotes express a cell surface glycoprotein,
T-DAF, that inhibits the assembly of C3 con-
vertases;2’11-13 and secondly, the verification that
IgM, the most powerful antibody class to activate
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Fig. 1. Activation of human C system in NHS by trypomastigotes (TF) of T. cruzi pre-opsonized with the Abs A1 (IgM, mAb H3G6), A2 (IgM, mAb
L1D10), A3 (IgG1, mAb L2B11), A4 (IgG2a mAb 6A2), A5 (IgG1, mAb B10.1), A6 (poly IgG anti-T, cruzl), A7 (total IMS anti-T, cruzl) or with
NHS (control-C). Total C consumption was measured by determining the numbers of CHso remaining in the samples of NHS incubated with
pre-opsonized TF using sheep red blood cells (E) presensitized with rabbit serum anti-E(EA) in pH 7.4 isotonic veronal buffered saline containing 0.1%
gelatin, 15 mM CaCI2 and 5 mM MgCI2 (VBS /) (panel A). The components C4 (panel B) and C3 (panel C) were measured by determining the
number of haemolytically active molecules (Z) remaining in the samples of NHS incubated with pre-opsonized TF using EACI or EACI42 intermediate
cells, respectively, in VBS containing 2.5% glucose (DGVBS//). Factor B (panel D)was measured by determining the number of haemolytically
active molecules (Z) remaining in the samples of NHS incubated with pre-opsonized TF using rabbit blood cells (Er) and NHS previously depleted of
factor B in DGVBS containing mM Mg and 10 mM EGTA.
Table 1. C-dependent lysis of the trypomastigote forms of
T. cruzi pre-opsonized with mouse monoclonal or polyclonal
antibodies against T. cruzi
Trypomastigotes of
T. cruzi optimized with"
% of killing
A1 (IgM mAb H3G6) 6
A2 (IgM mAb L1D10) 5
A3 (IgG1 mAb L2B11) 2
A4 (IgG2a mAb 6A2) 7
A5 (IgG1 mAb B10.1) 8
A6 (total IgG) 50
A7 (IMS) 72
A8 (IgM) 65
A9 (Fab#) 39
0
Trypomastigotes of T. cruzi were pre-opsonized with the
indicated Abs for 30 min at 4C and, after washing they were
reincubated with NHS for h at 37C. The number of motile
parasites were determined in a haemocytometer just before
(time, O) and after the incubation (time, h) and the percentage
of reduction was calculated. Each number represents the mean
of three experiments.
the classical pathway, also transforms trypomasti-
gotes into ACP activators.
21
Five mAbs that recognize and combine with
epitopes present on the trypomastigote cell surface,
although being able to activate the classical and the
alternative C pathways, were devoid of lytic
activity. In contrast, polyclonal anti-sera rich in lytic
activity or their purified IgG, IgM fractions and the
Fab# fragments were able to sensitize trypomasti-
gotes for total C, C4, B and C3 consumption, and
lysis. This observed ability of the polyclonal Abs
herein used cannot be due to its higher capacity to
interact with specific epitopes, as compared with the
monoclonal Abs, since recent reports have
demonstrated that human monoclonal Abs with
atalinity values of 1.8 x 10Sl/mol belonging to
IgG1, IgG3 and IgM isotypes were able to activate
the classical C pathway while those belonging to
IgA, IgG2 and to a lesser extent IgG4, but never
IgM, were able to activate the alternative pathway.
22
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Thus, all studied Abs were able to combine with
epitopes belonging to the trypanosome cell surface
but only some were endowed with the capacity to
trigger C-mediating lysis of opsonized parasites.
The C cascade activated by the Abs of the first
group could be under restrict control of RPC-like
molecules strategically distributed on the parasite
cell surface or is unable to form, or to insert, the
C5b-C9 complex into the parasite membrane. In
contrast, the Abs of the second group either
overpass the activity of the RPC-like molecules or
form C5b-C9 complexes in conditions to be
inserted in and hit the parasite membrane. Blockage
of the RPC-like molecules, for instance the T-DAF,
is the mechanism suggested for the trypanosome
killing activity exhibited by the latter group of
antibodies.
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